Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2014

View Archived Issues

Proteasome inhibition rescues a sarcolemmal repair protein in patients with muscular dystrophy

Generation of a transgenic mouse model of UBQLN2 mutation-related pathologies

Discovery of a novel TRPV1 antagonist as an analgesic

Double transgenic mouse model of MS used to assess ATX-MS-1467 effects

SYN-004, a novel, potent beta-lactamase, protects intestinal microflora in vivo

Phase IIb data for dupilumab in patients with atopic dermatitis reported

Novel 5-bromo-indirubins disclosed for non-small cell lung cancer

Biocept and Rosetta Genomics to evaluate microRNAs from circulating tumor cells

Cancer Genetics collaborates with Columbia University for myelodysplastic syndromes

Topline results reported from phase IIa study of LPCN-1111

Tobira Therapeutics doses first patient in phase IIb CENTAUR trial

Safety and pharmacokinetic analysis of N-91115 supports once-daily dosing

FDA accepts palbociclib NDA with priority review

Bristol-Myers Squibb, Pharmacyclics and Janssen to evaluate Opdivo and Imbruvica in NHL

Meda completes Rottapharm acquisition

VSV-EBOV Ebola vaccine begins phase I trials

Shantha's rotavirus vaccine enters phase III

Alnylam presents data from phase II extension study of patisiran in FAP

Novel anti-EGFR repebody for the detection and treatment of EGFR-expressing tumors

Dynavax Technologies begins phase I/II study of SD-101 in B-cell lymphoma

New Oncology and Gustave Roussy Cancer Campus collaborate on tumor genome profiling

Astellas collaborates with Harvard Medical School in retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...